What is William Blair’s Forecast for Amedisys Q1 Earnings?

Amedisys, Inc. (NASDAQ:AMED) – Research analysts at William Blair issued their Q1 2025 earnings per share estimates for shares of Amedisys in a research note issued to investors on Thursday, November 7th. William Blair analyst M. Larew anticipates that the health services provider will post earnings per share of $1.05 for the quarter. The consensus estimate for Amedisys’ current full-year earnings is $4.65 per share. William Blair also issued estimates for Amedisys’ Q2 2025 earnings at $1.40 EPS, Q4 2025 earnings at $1.26 EPS and FY2025 earnings at $4.80 EPS.

Amedisys (NASDAQ:AMED) last announced its earnings results on Wednesday, November 6th. The health services provider reported $1.00 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.19 by ($0.19). Amedisys had a net margin of 3.57% and a return on equity of 12.34%. The business had revenue of $587.67 million during the quarter, compared to the consensus estimate of $586.75 million. During the same period in the previous year, the firm posted $0.98 EPS. The company’s revenue was up 5.7% compared to the same quarter last year.

Other equities analysts have also issued research reports about the company. Deutsche Bank Aktiengesellschaft lowered Amedisys from a “buy” rating to a “hold” rating and set a $101.00 price objective on the stock. in a research note on Monday, July 29th. Cantor Fitzgerald reiterated a “neutral” rating and set a $101.00 price objective on shares of Amedisys in a research note on Thursday, July 25th. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $100.67.

Amedisys Stock Performance

Shares of NASDAQ:AMED opened at $96.71 on Friday. The company has a quick ratio of 1.16, a current ratio of 1.16 and a debt-to-equity ratio of 0.30. Amedisys has a 12-month low of $89.55 and a 12-month high of $98.95. The company’s 50 day moving average price is $96.70 and its two-hundred day moving average price is $95.85. The firm has a market cap of $3.17 billion, a PE ratio of 38.38, a PEG ratio of 1.92 and a beta of 0.78.

Institutional Investors Weigh In On Amedisys

A number of hedge funds have recently made changes to their positions in AMED. Amara Financial LLC. acquired a new position in shares of Amedisys during the third quarter worth $526,000. KBC Group NV bought a new position in Amedisys in the third quarter valued at about $63,000. State of New Jersey Common Pension Fund D boosted its stake in shares of Amedisys by 1.7% during the third quarter. State of New Jersey Common Pension Fund D now owns 20,357 shares of the health services provider’s stock valued at $1,965,000 after purchasing an additional 339 shares in the last quarter. Crossmark Global Holdings Inc. bought a new stake in shares of Amedisys during the third quarter worth about $243,000. Finally, State of Alaska Department of Revenue increased its stake in shares of Amedisys by 7.2% in the third quarter. State of Alaska Department of Revenue now owns 3,782 shares of the health services provider’s stock valued at $365,000 after buying an additional 255 shares during the period. 94.36% of the stock is currently owned by institutional investors and hedge funds.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.